TWI554519B - 新穎抗人類ｎｇｆ抗體 - Google Patents
新穎抗人類ｎｇｆ抗體 Download PDFInfo
- Publication number
- TWI554519B TWI554519B TW101128963A TW101128963A TWI554519B TW I554519 B TWI554519 B TW I554519B TW 101128963 A TW101128963 A TW 101128963A TW 101128963 A TW101128963 A TW 101128963A TW I554519 B TWI554519 B TW I554519B
- Authority
- TW
- Taiwan
- Prior art keywords
- fab
- fragment
- antibody
- human
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011176209 | 2011-08-11 | ||
| JP2011269215 | 2011-12-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201319086A TW201319086A (zh) | 2013-05-16 |
| TWI554519B true TWI554519B (zh) | 2016-10-21 |
Family
ID=47668585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101128963A TWI554519B (zh) | 2011-08-11 | 2012-08-10 | 新穎抗人類ｎｇｆ抗體 |
Country Status (30)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| WO2016190263A1 (ja) * | 2015-05-22 | 2016-12-01 | アステラス製薬株式会社 | 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント |
| EP3434283A4 (en) * | 2016-03-25 | 2019-11-13 | Astellas Pharma Inc. | MEDICAL COMPOSITION WITH A FAB 'FRAGMENT OF A HUMAN ANTI-NGF ANTIBODY AGAINST PEG |
| CN109929035B (zh) * | 2017-12-15 | 2022-06-28 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| JPWO2019221097A1 (ja) | 2018-05-15 | 2021-05-27 | アステラス製薬株式会社 | 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023540A1 (en) * | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69433422T2 (de) | 1993-03-11 | 2004-09-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Monoklonaler anti-hiv antikörper |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR20100132559A (ko) | 2001-05-30 | 2010-12-17 | 제넨테크, 인크. | 다양한 질환의 치료에 유용한 항-엔지에프 항체 |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| UA97086C2 (uk) | 2003-07-15 | 2012-01-10 | Емджен, Інк. | Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf) |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| JP5096167B2 (ja) | 2005-01-24 | 2012-12-12 | メドイミューン リミテッド | Ｎｇｆに対する特異的結合メンバー |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| ES2514319T3 (es) | 2009-05-04 | 2014-10-28 | Abbvie Research B.V. | Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada |
-
2012
- 2012-08-10 RS RS20180173A patent/RS56876B1/sr unknown
- 2012-08-10 KR KR1020147003155A patent/KR101999867B1/ko not_active Expired - Fee Related
- 2012-08-10 CA CA2841181A patent/CA2841181C/en active Active
- 2012-08-10 PH PH1/2014/500001A patent/PH12014500001A1/en unknown
- 2012-08-10 TW TW101128963A patent/TWI554519B/zh not_active IP Right Cessation
- 2012-08-10 LT LTEP12821758.5T patent/LT2743348T/lt unknown
- 2012-08-10 PL PL12821758T patent/PL2743348T3/pl unknown
- 2012-08-10 EA EA201490433A patent/EA024292B1/ru not_active IP Right Cessation
- 2012-08-10 NO NO12821758A patent/NO2743348T3/no unknown
- 2012-08-10 AR ARP120102927 patent/AR087506A1/es active IP Right Grant
- 2012-08-10 DK DK12821758.5T patent/DK2743348T3/en active
- 2012-08-10 MX MX2014001627A patent/MX351273B/es active IP Right Grant
- 2012-08-10 SI SI201231222T patent/SI2743348T1/en unknown
- 2012-08-10 AU AU2012293161A patent/AU2012293161B2/en not_active Ceased
- 2012-08-10 JP JP2013525474A patent/JP5376095B2/ja not_active Expired - Fee Related
- 2012-08-10 ES ES12821758.5T patent/ES2663968T3/es active Active
- 2012-08-10 EP EP12821758.5A patent/EP2743348B1/en active Active
- 2012-08-10 WO PCT/JP2012/070433 patent/WO2013022083A1/ja not_active Ceased
- 2012-08-10 SM SM20180166T patent/SMT201800166T1/it unknown
- 2012-08-10 HU HUE12821758A patent/HUE036079T2/hu unknown
- 2012-08-10 HR HRP20180155TT patent/HRP20180155T1/hr unknown
- 2012-08-10 BR BR112014002576-2A patent/BR112014002576B1/pt not_active IP Right Cessation
- 2012-08-10 CN CN201280039293.3A patent/CN103748222B/zh not_active Expired - Fee Related
- 2012-08-10 PT PT128217585T patent/PT2743348T/pt unknown
- 2012-08-10 ME MEP-2018-28A patent/ME02944B/me unknown
- 2012-08-10 IN IN614CHN2014 patent/IN2014CN00614A/en unknown
- 2012-08-10 US US13/879,267 patent/US8986952B2/en active Active
-
2014
- 2014-01-30 ZA ZA2014/00741A patent/ZA201400741B/en unknown
- 2014-02-03 IL IL230797A patent/IL230797A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/596,874 patent/US20150218265A1/en not_active Abandoned
-
2018
- 2018-02-14 CY CY20181100180T patent/CY1119914T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023540A1 (en) * | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201319086A (zh) | 新穎抗人類ｎｇｆ抗體 | |
| US9127055B2 (en) | Method of treating pain with anti-human NGF antibody | |
| JP2020510432A (ja) | Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用 | |
| JP6040943B2 (ja) | 新規抗ヒトｃｔｇｆ抗体 | |
| TWI432453B (zh) | 改良型人化抗人α９整連蛋白抗體 | |
| US11260124B2 (en) | Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF | |
| JP6135161B2 (ja) | 新規抗ヒトｎｇｆ抗体 | |
| JP7119225B2 (ja) | Ｐｄｇｆ受容体に対する抗体およびその用途 | |
| WO2011004847A1 (ja) | 新規ヒト化抗ヒトα９インテグリン抗体 | |
| CN118496364A (zh) | uPARAP特异性结合蛋白及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |